In January 2017, in connection with a change in management
responsibility for certain product lines, the company transferred
its plastics for cell culture and vaccines/biologics; sample
preparation and analysis; and production chemicals product lines to
the Life Sciences Solutions segment from the Laboratory Products
and Services segment and transferred its biochemical product line
from the Life Sciences Solutions segment to the Laboratory Products
and Services segment. These moves are consistent with the companys
historical practice of moving a product line between segments when
a shift in strategic focus of either the product line or a segment
more closely aligns the product line with a segment different than
that in which it had previously been reported. Prior period segment
information has been reclassified to reflect these
transfers.>The results of the transferred product lines were
reported as part of their new segment for each period presented in
the companys first quarter 2017 Quarterly Report on Form 10-Q filed
with the SEC on May 5, 2017.

On January 1, 2017, the company adopted new accounting guidance, as
described in Note 1 to the financial statements included in Exhibit
99.1 of this Form 8-K, which was applied to the statement of cash
flows retrospectively. Prior period cash flows have been
reclassified to reflect adoption of this guidance.

Exhibit 99.1 of this Form 8-K updates Items 7, 8 and 15(a) of the
companys Annual Report on Form 10-K for the year ended December 31,
2016 (the 2016 Form 10-K), which was filed with the Securities and
Exchange Commission on February 28, 2017, to reflect the
reclassification of segment information and cash flows discussed
above. The segment reclassification and adoption of new accounting
guidance had no effect on the companys historical reported net
income or earnings per share.

The information set forth in Exhibit 99.1 continues to report and
disclose information as of February 28, 2017, the date the 2016
Form 10-K was filed, and the company has not updated or amended the
disclosures contained therein to reflect events that have occurred
since the filing of the 2016 Form 10-K, or modified or updated
those disclosures in any way other than as required to update the
segment disclosures and statement of cash flows for all periods
presented to reflect the items described above. Accordingly,
Exhibit 99.1 should be read in conjunction with the companys
filings made with the SEC subsequent to the filing of the 2016 Form
10-K.

This Current Report on Form 8-K contains forward-looking statements
that involve a number of risks and uncertainties. Important factors
that could cause actual results to differ materially from those
indicated by such forward-looking statements are set forth in the
companys Quarterly Report on Form 10-Q for the quarter ended April
1, 2017, under the caption Risk Factors, which is on file with the
Securities and Exchange Commission and available in the Investors
section of our Website under the heading SEC Filings. Important
factors that could cause actual results to differ materially from
those indicated by forward-looking statements include risks and
uncertainties relating to: the need to develop new products and
adapt to significant technological change; implementation of
strategies for improving growth; general economic conditions and
related uncertainties; dependence on customers capital spending
policies and government funding policies; the effect of exchange
rate fluctuations on international operations; use and protection
of intellectual property; the effect of changes in governmental
regulations; and the effect of laws and regulations governing
government contracts as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected. While we may elect to update
forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so, even if our
estimates change and, therefore, you should not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits